CoChat

Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor

Open access
Kim, Teresa S., Cavnar, Michael J., Cohen, Noah A., Sorenson, Eric C., Greer, Jonathan B., Seifert, Adrian M., Crawley, Megan H., Green, Benjamin L., Popow, Rachel, Pillarsetty, Nagavarakishore, Veach, Darren R., Ku, Anson T., Rossi, Ferdinand, Besmer, Peter, Antonescu, Cristina R., Zeng, Shan, DeMatteo, Ronald P. · 2014 · Clinical Cancer Research
Cited by 52

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and a model of targeted molecular therapy. GIST depends on oncogenic KIT signaling and responds to the tyrosine kinase inhibitor imatinib. However, imatinib is rarely curative. We hypothesized that PLX3397, which inhibits KIT and colony-stimulating-factor-1 receptor (CSF1R), would be more efficacious than imatinib in GIST by also depleting tumor-associated macrophages, which are generally thought to support tumor growth. Experimental Design: We treated KitV558del/+ mice that develop GIST or mice with subcutaneous human GIST xenografts with imatinib or PLX3397 and analyzed tumor weight, cellular composition, histology, molecular signaling, and fibrosis. In vitro assays on human GIST cell lines were also performed. Results: PLX3397 was more effective than imatinib in reducing tumor weight and cellularity in both KitV558del/+ murine GIST and human GIST xenografts. The superiority of PLX3397 did not depend on depletion of tumor-associated macrophages, because adding CSF1R inhibition did not improve the effects of imatinib. Instead, PLX3397 was a more potent KIT inhibitor than imatinib in vitro. PLX3397 therapy also induced substantial intratumoral fibrosis, which impaired the subsequent delivery of small molecules. Conclusions: PLX3397 therapy has greater efficacy than imatinib in preclinical GIST models and warrants study in patients with GIST. The resultant intratumoral fibrosis may represent one of the barriers to achieving complete tumor eradication. Clin Cancer Res; 20(9); 2350–62. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-3033

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 52

Metadata

Authors
Kim, T. S., Cavnar, M. J., Cohen, N. A., Sorenson, E. C., Greer, J. B., Seifert, A. M., Crawley, M. H., Green, B. L., Popow, R., Pillarsetty, N., Veach, D. R., Ku, A. T., Rossi, F., Besmer, P., Antonescu, C. R., Zeng, S., & DeMatteo, R. P.
Venue
Clinical Cancer Research
Published
2014-04-30
Volume
20
Issue
9
Pages
2350-2362
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2138153563
Cited by
52
References
5
FWCI
6.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-3033
The paper
Kim, T. S., Cavnar, M. J., Cohen, N. A., Sorenson, E. C., Greer, J. B., Seifert, A. M., Crawley, M. H., Green, B. L., Popow, R., Pillarsetty, N., Veach, D. R., Ku, A. T., Rossi, F., Besmer, P., Antonescu, C. R., Zeng, S., & DeMatteo, R. P. (2014). Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-3033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.